Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Operating Leases (2019 - 2025)

Aptevo Therapeutics' Operating Leases history spans 7 years, with the latest figure at $4.0 million for Q3 2025.

  • For Q3 2025, Operating Leases fell 16.67% year-over-year to $4.0 million; the TTM value through Sep 2025 reached $4.0 million, down 16.67%, while the annual FY2024 figure was $4.6 million, 14.23% down from the prior year.
  • Operating Leases for Q3 2025 was $4.0 million at Aptevo Therapeutics, down from $4.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $6.4 million in Q2 2022 and bottomed at $1.1 million in Q1 2022.
  • The 5-year median for Operating Leases is $4.8 million (2024), against an average of $4.3 million.
  • The largest annual shift saw Operating Leases crashed 48.09% in 2022 before it skyrocketed 436.36% in 2023.
  • A 5-year view of Operating Leases shows it stood at $1.3 million in 2021, then surged by 369.23% to $6.1 million in 2022, then decreased by 11.52% to $5.4 million in 2023, then dropped by 14.23% to $4.6 million in 2024, then dropped by 13.59% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Operating Leases are $4.0 million (Q3 2025), $4.2 million (Q2 2025), and $4.4 million (Q1 2025).